Rep. Bilirakis: Recognizing the Importance of the Orphan Drug Act's Exclusivity Incentives in Rare Disease Therapy Development
February 19, 2025
February 19, 2025
WASHINGTON, Feb. 19 -- Rep. Gus M. Bilirakis, R-Florida, posted the following statement in the extensions of remarks section of the Congressional Record on Feb. 18, 2025:
* * *
Mr. Speaker, in honor of February marking Rate Disease Month, I rise today to reaffirm the critical importance of the Orphan Drug Act's exclusivity incentive to the development of life-changing therapies for patients with rare diseases.
Congress designed the Orphan Drug Act to p . . .
* * *
Mr. Speaker, in honor of February marking Rate Disease Month, I rise today to reaffirm the critical importance of the Orphan Drug Act's exclusivity incentive to the development of life-changing therapies for patients with rare diseases.
Congress designed the Orphan Drug Act to p . . .